
MYNZ
Healthcare · Diagnostics & Research · $10.6M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2025
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 7, 2026 | Time not confirmed | -2.00 | 0.00 | +100.0% |
| Nov 28, 2025 | Time not confirmed | -2.00 | 0.00 | +100.0% |
| Sep 3, 2025 | Time not confirmed | -2.40 | -2.65 | -10.4% |
| May 30, 2025 | Time not confirmed | -2.80 | -7.71 | -175.4% |
| Mar 31, 2025 | Time not confirmed | -6.40 | -7.71 | -20.5% |
| Oct 21, 2024 | Time not confirmed | -0.15 | -19.60 | -12966.7% |
| Apr 9, 2024 | Before the open | -0.32 | -0.24 | +25.0% |
| Mar 6, 2024 | Time not confirmed | -0.32 | -0.24 | +24.2% |
| Nov 16, 2023 | Before the open | -0.47 | -0.39 | +17.0% |
| Aug 15, 2023 | Before the open | -0.42 | -0.56 | -33.3% |
| Apr 27, 2023 | Before the open | -0.46 | -0.45 | +2.2% |
| Mar 8, 2023 | Time not confirmed | -0.46 | -0.46 | 0.0% |
| Nov 2, 2022 | Before the open | -0.43 |
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to…
| -0.43 |
| 0.0% |
| Sep 7, 2022 | Before the open | -0.46 | -0.46 | 0.0% |
| May 2, 2022 | After the close | -0.49 | -0.84 | -71.4% |
| Jan 28, 2022 | After the close | 0.00 | -0.03 | — |
| Nov 12, 2021 | Time not confirmed | — | -0.02 | — |
| Jun 30, 2021 | Time not confirmed | 0.00 | -0.12 | — |